Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 9989)

$\mathbf{T}\mathbf{A}$ \mathbf{A}			T	\mathbf{T}		T		
T	В	T	\mathbf{A}	\mathbf{A}		T	ΤÆ	TT

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the " ,", together with its subsidiaries referred to as the " .") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

On March 30, 2023, Techdow USA Inc. ("T A"), a wholly-owned subsidiary of the Company, entered into a distribution and supply agreement (the "A") with Chia Tai Tianqing Pharmaceutical Group Co. Ltd. ("TT"), pursuant to which CTTQ agreed to grant to Techdow USA a license to commercialize Fosaprepitant Dimeglutide (the "") in the United States.

Under the Distribution Agreement, Techdow USA will be responsible for the commercialization of the Drug in the United States market, including marketing, promotion, sales and distribution of the Drug. At the same time, Techdow USA agreed to purchase the Drug from CTTQ at an agreed price and share an agreed percentage of the net profit from the sale of the Drug with CTTQ.

The Drug is a neurokinin-1 receptor blocker used in the prevention and treatment of nausea and vomiting caused by highly emetogenic chemotherapy (HEC) regimens. It is generally recommended under international guidelines that the triple regimen of NK-1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone as the first-line antiemetic regimen.

B TA ATTTE A


This cooperation is the result of careful consideration by the Group based on the combination of the Company's development strategy and market research. In the United States market, the sales model and channels of the Drug are fully consistent with those of the standard heparin finished doses, so for the Group's self-operated team in the United States, there is a high degree of synergy in the sales of the Drug and the Company's heparin finished doses. The Company can leverage its established self-operated sales network and channels to promote and sell the Drug with a low increase in sales costs.

Techdow USA's strategic cooperation with CTTQ under the Distribution Agreement is a representation and exploration of the Group's strategy of insisting on international operation and assisting Chinese pharmaceutical companies to expand into the European and American markets. The Group has established comprehensive self-operated teams in five European countries and the United States, and has an established self-operated sales network and channels. This cooperation is a recognition of the Group's marketing capabilities in overseas markets, and also an important opportunity for the Company to accumulate experience in exploring overseas marketing, which has far-reaching and positive significance for the Group's future cooperation with other pharmaceutical companies.

AT TT

CTTQ is an innovative pharmaceutical company principally engaged in the research and development, production and sales of innovative and high-quality medicines, and is a principal subsidiary of Sino Biopharmaceutical Limited, a company listed on the Stock Exchange (stock code: 1177). CTTQ is committed to providing patients with better health solutions and affordable medical resources.

Announcement is hereby given.



Shenzhen, the PRC April 3, 2023

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.